mutations and sophisticated kar yotype. It follows a linear evolution in the CLL clone throughout the recurrent acquisition of CDKN2A Not all individuals with CLL need therapy. Despite all new improvements, the iwCLL still endorses watchful observation for sufferers with asymptomatic disease.86 T